Article
Loss of TET2 with reduced genomic 5-hmC is associated with adverse-risk AML.
Leukemia & lymphoma - 1 Dec 2022
Pethusamy Karthikeyan, Seethy Ashikh, Dhar Ruby, Karmakar Abhibroto, Chaudhary Shilpi, Bakhshi Sameer, Palanichamy Jayanth Kumar, Chopra Anita, Chauhan Shyam S, Karmakar Subhradip
Abstract excerpt
While considerable information exists on the ten-eleven translocation 2 (TET2) mutational landscape in AML, the information on TET2 expression is limiting. So, we aimed to study the TET2 expression at mRNA and protein levels in AML patients compared to healthy controls. To achieve this, we recruited 70 non-M3, de novo AML patients and 20 healthy controls. The expression of TET2 was checked at mRNA and protein...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.